CURRENT CONCEPT OF MASTOCYTOSIS
DOI:
https://doi.org/10.54890/.v1i1.60Abstract
The article presents modern data on cutaneous and systemic forms of mastocytosis. Mastocytosis is a rare disease. The most common variants are cutaneous and indolent systemic mastocytosis, less often obesity leukemia. The clinical picture of mastocytosis is heterogeneous – from skin lesions that can spontaneously progress to aggressive forms of the disease associated with organ failure and a short life span. According to the WHO classification (2016), 7 subtypes of mastocytosis have been identified. It is diagnosed on the basis of clinical manifestations and the detection of infiltrates of tumor mast cells using morphological, immunohistochemical, immunophenotypic, genetic and molecular methods. Treatment of mastocytosis requires a deep understanding of their molecular and cellular pathogenesis and accurate diagnostic assessment.
Keywords:
mastocytosis, a symptom of Darier-Unna, treatment, Cetirizine, Midostaurin.References
1.Valent P. Diagnosis and treatment of systemic mastocytosis: state of the art [Text] / P. Valent, C. Akin, W.R. Sperr // Br J Haematol. - 2003. - Vol. 122 (5) - P. 695–717.
2.Cohen S.S. Epidemiology of systemic mastocytosis in Denmark [Text] / S.S. Cohen, S. Skovbo, H. Vestergaard // Br J Haematol. - 2014. - Vol. 166 (4). - P. 521–528.
3.Asati D.P. Bullous mastocytosis in a 3-month-old infant [Text] / D.P. Asati, A. Tiwari // Indian Dermatol Online J. - 2014. - Vol. 5 (4). - P. 497–500.
4.Valent P. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria [Text] / P. Valent, C. Akin, L. Escribano // Eur J Clin Invest. - 2007. - Vol. 37 (6). - P. 435–453.
5.Extensive blistering is a predictor for severe complications in children with mastocytosis Text] / [K. Brockow, J. Ring, I. Alvarez-Twose et al.] // Allergy. - 2012. - Vol. 67 (10). - P. 1323–1324.
6.Мастоцитоз у детей [Текст] / [Т.Ю. Лебедева, О.Б. Федерякина, В.В. Дубенский и др.] // Тверской медицинский журнал. - 2014. - Т. 2, №1. - С. 48–61.
7.Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis [Text] / K. Brockow // Immunol Allergy Clin North Am. - 2014. - Vol. 34 (2). - P. 283–295.
8.Gupta М. Blisters, Vaccines, and Mast Cells: A Difficult Case of Diffuse Cutaneous Mastocytosis [Text] / М. Gupta, C. Akin, G.M. Sanders // J Allergy Clin Immunol Pract. - 2019. - Vol. 7 (4). P. 1370–1372.
9.Bodemer C. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations [Text] / C. Bodemer, O. Hermine, F. Palmerini // J Invest Dermatol. - 2010. - Vol. 130 (3). - P. 804–815.
10.Horny H.P. World Health Organization (WHO) classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues [Text] / H.P. Horny, C. Akin, D. Arber // Lyon: IARC Press. - 2016.
11.Valent P. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future [Text] / P. Valent, C. Akin, K. Hartmann // Cancer Res. - 2017. - No. 77. - P. 1261–1270.
12.Mastocytosis (mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues [Text] / [H.P. Horny, C. Akin, D.D. Metcalfe et al.] // IARC Press; Lyon, France. - 2008. - Vol. 2 (2). - P. 54-63.
13.Current Treatment Options in Patients With Mastocytosis: Status in 2015 and Future Perspectives [Text] / [M. Arock, C. Akin, O. Hermine et al.] // Eur J Haematol. - 2015. - Vol. 94. (6). - P. 474–490.
14.Lange M. Mastocytosis in children and adults: clinical disease heterogeneity [Text] / M. Lange, B. Nedoszytko, A. Gorska // Arch Med Sci. - 2012. - Vol. 8 (3). - P. 533–541.
15.Охотникова Е.Н. Системный мастоцитоз у детей: редкость, сущность, клиническая презентация и последствия (клинический случай) [Текст] / Е.Н. Охотникова, К.В. Меллина, Е.В. Поночевная // Педиатрия. Восточная Европа. - 2018. - Т. 6, № 4. - С. 594–612.
16.Wilson T.M. Clonal analysis of NRAS activating mutations in KITD816V systemic mastocytosis [Text] / T.M. Wilson, I. Maric, O. Simakova // Haematologica. - 2011. - Vol. 96 (3). - P. 459–463.
17.Castells M. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations [Text] / M. Castells, D.D. Metcalfe, L. Escribano // American Journal of Clinical Dermatology. - 2011. - Vol. 12 (4). - P. 259–270.
18.Arber D.A. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [Text] / D.A. Arber // Blood. - 2016. - Vol. 127 (20). - P. 2391–2405.
19.Hartmann K. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology [Text] / K. Hartmann // Journal of Allergy and Clinical Immunology. - 2016. - Vol. 137 (1). - P. 35–45.
20.Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis [Text] / [J. Gotlib, H.C. Kluin-Nelemans, T.I. George et al.] // The New England journal of Medicine. - 2016. - Vol. 374 (26). - P. 2530–2541.
21.In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V [Text] / [A. Bцhm, K. Sonneck, K.V. Gleixner et al.] // Experimental Hematology. - 2010. - Vol. 38 (9). - P. 744–55.
22.Скрипкина Ю.К., Бутова Ю.С., Иванова О.Л. Дерматовенерология. Национальное руководство // - М.: ГЭОТАР-Медиа. - 2013. - 896 с.
23.Халиуллин Ю.Г. Мастоцитоз: клинические проявления, методы диагностики и тактика ведения пациентов [Текст] / Ю.Г. Халиуллин // Лечащий врач. - 2012. - №8. - С. 83–90.
24.Pardanani A. Systemic mastocytosis: evolving lessons from large patient registry datasets [Text] / A. Pardanani // Am. J. Hematol. - 2016. - Vol. 91 (7). - P. 654-5
Downloads
Published
How to Cite
Issue
Section
